

## IN THE CLAIMS

1. (currently amended) A method of producing an immune response in a mammal, comprising the step of:

administering mucosally to a mammal an admixture comprising ~~a protein~~ an immunogen and a plant lectin selected from the group consisting of ML-I, ML-II, ML-III, and UEA-I, whereby the mammal produces an immune response to the ~~protein~~ immunogen which is greater relative to the immune response to the ~~protein~~ immunogen produced in the absence of the plant lectin.

2. (canceled)

2 ~~3~~. (previously amended) The method of claim 1 wherein the admixture is administered intranasally.

3 ~~4~~. (previously amended) The method of claim 1 wherein the plant lectin is ML-I.

4 ~~5~~. (original) The method of claim 1 wherein the mammal is selected from the group consisting of a dog, a cat, a mouse, a rat, a rabbit, a guinea pig, a chimpanzee, a baboon, and a human.

5 ~~6~~. (original) The method of claim 1 wherein the immune response is a T cell response.

6 ~~7~~. (original) The method of claim <sup>5</sup>~~6~~ wherein the T cell response is a Th2 response.

7 ~~8~~. (original) The method of claim <sup>5</sup>~~6~~ wherein the T cell response is proliferation of T cells.

8 ~~9~~. (original) The method of claim 1 wherein the immune response is an antibody response.

9 ~~10~~. (previously amended) The method of claim <sup>8</sup>~~9~~ wherein the response is an IgG response.

10 11. (previously amended) The method of claim <sup>9</sup>10 wherein the IgG antibodies are IgG1 antibodies.

11 12. (original) The method of claim <sup>9</sup>10 wherein the antibodies are detectable in serum.

12 13. (original) The method of claim <sup>9</sup>10 wherein the antibodies are detectable in mucosal secretion.

13 14. (previously amended) The method of claim <sup>12</sup>13 wherein the mucosal secretion is obtained from a gut mucosa.

14 15. (previously amended) The method of claim 1 wherein the admixture comprises two or more different lectins.

15 16. (previously amended) The method of claim 1 wherein the admixture comprises two or more different immunogens.

16 17. (currently amended) The method of claim 1 wherein the ~~protein~~ immunogen is a protein of an infectious agent.

17 18. (previously amended) The method of claim <sup>16</sup>17 wherein the infectious agent is a virus.

18 19. (previously amended) The method of claim <sup>16</sup>17 wherein the immunogen is a glycoprotein D2 protein from a *Herpes simplex* virus type 2.

19 20. (original) The method of claim <sup>2</sup>19 wherein the admixture is administered using a nasal spray.

20 21. (original) The method of claim <sup>2</sup>20 wherein a drop of a liquid containing the admixture is administered.

21 22. (original) The method of claim 1 wherein at least two doses of the admixture are administered.

~~22~~ ~~23~~. (currently amended) The method of claim 1 wherein the admixture comprises a protein the immunogen and a the plant lectin in a ratio of at least about 1:1.

~~23~~ ~~24~~. (previously amended) The method of claim ~~23~~<sup>22</sup> wherein the ratio is at least about 10:1.

~~24~~ ~~25~~. (original) The method of claim ~~9~~<sup>8</sup> wherein an antibody titer is measured using an ELISA.

~~26-29~~. (canceled)

~~25~~ ~~30~~. (original) The method of claim 1 wherein the admixture is administered in conjunction with a bioadhesive polymer.

~~26~~ ~~31~~. (original) The method of claim 1 wherein the admixture is in an enteric formulation.

~~27~~ ~~32~~. (previously added) The method of claim 1 wherein the plant lectin is ML-II.

~~28~~ ~~33~~. (previously added) The method of claim 1 wherein the plant lectin is ML-III.

~~34~~. (canceled)

~~29~~ ~~35~~. (previously added) The method of claim 1 wherein the plant lectin is UEA-I.

~~30~~ ~~36~~. (previously added) The method of claim ~~3~~<sup>4</sup> wherein the mammal is a mouse.

~~31~~ ~~37~~. (previously added) The method of claim ~~5~~<sup>4</sup> wherein the mammal is a human.

~~32~~ ~~38~~. (previously added) The method of claim ~~9~~<sup>8</sup> wherein the antibody response is an IgA response.

~~33~~ ~~39~~. (previously added) The method of claim ~~10~~<sup>9</sup> wherein the IgG antibodies are IgG2a antibodies.

~~34~~ ~~40~~. (previously added) The method of claim ~~10~~<sup>9</sup> wherein the IgG antibodies are IgG2b antibodies.

35 41. (previously added) The method of claim <sup>12</sup>13 wherein the mucosal secretion is obtained from a vaginal mucosa.

36 42. (previously added) The method of claim <sup>12</sup>13 wherein the mucosal secretion is obtained from an oral mucosa

37 43. (previously added) The method of claim <sup>12</sup>13 wherein the mucosal secretion is obtained from a nasal mucosa.